Skip to main content

Table 1 Clinical and demographic characteristics

From: FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1

Characteristic H12O series
(N = 251 patients)
METABRIC (hormone-positive, Lum-A or Lum-B subset)
(N = 998 patients)
Age (median, range) 54.0 (20.2–91.0) 63.9 (26.3–90.4)
Tumor size
 T1 126 (50.2%) 440 (44.0%)
 T2 96 (38.2%) 519 (52.0%)
 T3 23 (9.1%) 36 (3.6%)
 T4 6 (2.4%) N/A**
 N/A 0 (0%) 5 (0.5%)
Nodal status
 N0 108 (43.1%) 540 (54.0%)
 N1 85 (33.9%) 313 (31.3%)
 N2 38 (15.1%) 105 (10.5%)
 N3 20 (7.9%) 40 (4.0%)
Grade
 G1 63 (25.1%) 127 (12.7%)
 G2 126 (50.2%) 502 (50.3%)
 G3 62 (24.7%) 326 (32.6%)
 N/A 0 (0%) 44 (4.4%)
Lum-A/B (defined by Ki67% staining)
 < 15% (Lum-A) 124 (49.4%) N/A
 > 14% (Lum-B) 127 (50.6%)  
Lum-A/B (defined by PAM-50)
 Lum-A N/A 635 (63.6%)
 Lum-B   363 (36.4%)
Adjuvant/neoadjuvant chemotherapy
No 63 (25.1%) 920 (92.2%)
Yes 188 (74.9%) 78 (7.8%)
CMF or capecitabine 38 (15.1%) 14 (1.4%)
Anthracycline based 87 (34.7%) 38 (3.8%)
Taxane based 63 (25.1%) 4 (0.4%)
Other 0 (0%) 22 (2.2%)
Adjuvant hormonal therapy
 No 13 (5.2%) 273 (27.4%)
 Yes 238 (94.8%) 725 (72.6%)
FGFR1 amplified* 195/251 available (77.7%) 998/998 available (100%)
 No 172 (88.2%) 922 (92.4%)
 Yes 23 (11.8%) 76 (7.6%)
FGFR1 RNAscope positivity 165/251 available (65.7%)  
 Negative (0, 1+, or 2+) 137 (83%) N/A
 Positive (3+ or 4+) 28 (17%) N/A
Relapse
 No 169 (73.3%) 627 (62.8%)
 Yes 82 (32.7%) 370 (37.1%)
 N/A 0 (0%) 1 (0.1%)
  1. *FGFR amplification was determined in the H12O series by FISH in a tissue microarray. Conversely, in the METABRIC series, it was determined by CGH arrays. FISH data were not available in 56 cases; thus, positive/negative cases are shown in relative percentage to the available cases
  2. **In the METABRIC database, primary tumor is coded by size in millimeters. What qualifies a primary tumor as T4 is the invasion of the chest wall and/or skin and/or presence of inflammatory carcinoma, regardless of the tumor size in millimeters. Thus, the number of T4 tumors in this series is actually unknown, although the percentage of T4 tumors in routine clinics is generally low